Novo Nordisk’s Pipeline Pivot: How a Pill, a Weekly Insulin, and an AI Bet Are Reshaping the Obesity Giant

The headline numbers from Novo Nordisk’s first-quarter report tell a story of explosive growth, but the real narrative is far more nuanced. A 32% revenue surge and a sharp jump in operating profit were largely the work of a one-off accounting adjustment—a $4.2 billion reversal of provisions tied to US pricing mechanisms. Strip that out, and the picture shifts dramatically: currency-adjusted sales actually shrank by 4%, while adjusted operating profit slipped 6% and gross margins contracted to 80.6%.

The culprit is familiar. Intense pricing pressure in the US diabetes market has taken a toll, with adjusted American revenues falling 11% on a currency-neutral basis. Yet even as the core business struggles, the Danish drugmaker is quietly engineering a transformation that extends far beyond its blockbuster Wegovy franchise.

The Pill That Rewrote the Launch Playbook

The standout performer of the quarter was undoubtedly the oral version of Wegovy, introduced in early January. With over 2 million prescriptions written since launch, it has become the strongest volume debut of any GLP-1 drug in US history. The pill contributed 2.26 billion Danish kroner to first-quarter sales, roughly double what Jefferies analyst Michael Leuchant had anticipated.

CEO Mike Doustdar argues that the tablet is not cannibalising the injectable version but complementing it. Patients are using both forms in parallel, creating what he describes as a synergistic effect. That dynamic helped lift adjusted revenues in the obesity segment by 22%, providing a crucial counterweight to the weakness in diabetes.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

A New Insulin Enters the Ring

Beyond Wegovy, Novo Nordisk is broadening its metabolic arsenal. The US Food and Drug Administration recently approved Awiqli, the first weekly basal insulin to reach the market. The company plans to launch the product in the second half of 2026, and analysts project annual sales could reach $3 billion.

The timing is strategic. In March, the FDA also cleared a high-dose version of Wegovy, Wegovy HD, which delivered an average weight loss of nearly 21% in clinical trials. That approval came just weeks before rival Eli Lilly launched its own oral obesity drug, Foundayo, in early April.

Generics Are Circling

The urgency behind these pipeline moves is clear. Semaglutide, the active ingredient in both Wegovy and Ozempic, is losing patent protection in several countries this year. Generic competitors have already entered the market in India, where low-cost copies are undercutting Novo Nordisk’s pricing. Only China, protected until April 2027, remains a safe harbour for now.

To prepare for life after Semaglutide, the company is advancing a slate of next-generation candidates. The experimental drug Etavopivat, aimed at sickle cell disease, met all primary endpoints in a late-stage trial. Meanwhile, Novo Nordisk has initiated a Phase 3 programme for Zenagamtid, a new obesity treatment that could eventually succeed Wegovy.

AI and the Search for Speed

Research and development are getting a technological boost. Novo Nordisk has struck a partnership with OpenAI to deploy artificial intelligence across its operations. The AI will analyse complex datasets and accelerate drug discovery, with pilot projects already underway in research and manufacturing. Management aims to fully integrate the technology by the end of 2026.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

A Cautiously Raised Outlook

The strong uptake of the oral Wegovy has prompted a modest upward revision to full-year guidance. Novo Nordisk now expects a decline in adjusted sales and operating profit of between 4% and 12%, an improvement from the previous forecast of a decline of up to 13%.

Investors have taken note. The stock closed 2% higher on the day of the earnings release, and over the past month the shares have rallied 21% to €39.07, comfortably clearing the 50-day moving average. Still, the stock remains about 33% below its level of a year ago.

The next major catalyst comes in mid-May, when Novo Nordisk presents real-world data at the European Congress on Obesity in Istanbul. With the company currently commanding a 65% share of new US prescriptions, those results will be critical in determining whether it can fend off Eli Lilly’s encroachment—and whether the pipeline pivot is enough to sustain its dominance.

Ad

Novo Nordisk Stock: New Analysis - 8 May

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69290893 |